Peptides, Big Pharma & the Future of Longevity

Peptides have become one of the most talked-about areas at the intersection of emerging science, medicine, performance and longevity—but the conversation is often more complicated than either the hype or the skepticism suggests.

In the first episode of Beyond the Drop, Dennis Weber explores why peptides have attracted so much attention, how pharmaceutical development intersects with emerging peptide research, and what happens when real-world interest begins moving faster than large-scale clinical evidence.

The episode isn't about assuming every claim surrounding peptides is true. It's about asking better questions: What does the research actually show? What remains uncertain? Why do some compounds generate enormous interest long before the evidence is complete? And how should we think about the gap between laboratory research, personal observations and controlled human studies?

That's the territory Beyond the Drop will continue exploring—peptides opened the door; now we want to know what's on the other side.